TITLE

Gilbert Syndrome and the Development of Antiretroviral Therapy--Associated Hyperbilirubinemia

AUTHOR(S)
Rotger, Margalida; Taffé, Patrick; Bleiber, Gabriela; Günthard, Huidrych F.; Furrer, Hansjakob; Vernazza, Pietro; Drechsler, Henning; Bernasconi, Enos; Rickenbach, Martin; Telenti, Amalio
PUB. DATE
October 2005
SOURCE
Journal of Infectious Diseases;10/15/2005, Vol. 192 Issue 8, p1381
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background. Unconjugated hyperbilirubinemia results from Gilbert syndrome and from antiretroviral therapy (ART) containing protease inhibitors. An understanding of the interaction between genetic predisposition and ART may help to identify individuals at highest risk for developing jaundice. Methods. We quantified the contribution of UGT1A1*28 and ART to hyperbilirubinemia by longitudinally modeling 1386 total bilirubin levels in 96 human immunodeficiency virus (HIV)-infected individuals during a median of 6 years. Results. The estimated average bilirubin level was 8.8 μmol/L (0.51 mg/dL). Atazanavir increased bilirubin levels by 15 μmol/L (0.87 mg/dL), and indinavir increased bilirubin levels by 8 μmol/L (0.46 mg/dL). Ritonavir, lopinavir, saquinavir, and nelfinavir had no or minimal effect on bilirubin levels. Homozygous UGT1A1*28 increased bilirubin levels by 5.2 μmol/L (0.3 mg/dL). As a consequence, 67% of individuals homozygous for UGT1A1*28 and receiving atazanavir or indinavir had ⩾2 episodes of hyperbilirubinemia in the jaundice range (>43 μmol/L [>2.5 mg/dL]), versus 7% of those with the common allele and not receiving either of those protease inhibitors (P< .001). Efavirenz resulted in decreased bilirubin levels, which is consistent with the induction of UDP-glucuronosyltransferase 1A1. Conclusions. Genotyping for UGT1A1*28 before initiation of ART would identify HIV-infected individuals at risk for hyperbilirubinemia and decrease episodes of jaundice.
ACCESSION #
18543996

 

Related Articles

  • Liver Toxicity of Initial Antiretroviral Drug Regimens Including Two Nucleoside Analogs Plus One Non-Nucleoside Analog or One Ritonavir-Boosted Protease Inhibitor in HIV/HCV-Coinfected Patients. Macías, Juan; Neukam, Karin; Mallolas, Josep; López-Cortés, Luis F.; Cartón, José A.; Domingo, Pere; Moreno, Santiago; Iribarren, José A.; Clotet, Bonaventura; Crespo, Manell; de Los Santos, Ignacio; Ortega, Enrique; Knobel, Hernando; Jiménez-Expósito, María J.; Pineda, Juan A.; on behalf of the COINS Study Team*, Juan // HIV Clinical Trials (Thomas Land Publishers Incorporated);Mar/Apr2012, Vol. 13 Issue 2, p61 

    Objective: To evaluate the incidence and risk factors for grade 3 or 4 ALT or AST elevations (TE) and grade 4 total bilirubin elevations (TBE) among HIV/HCV- coinfected treatment-naïve patients with an initial regimen including 2 nucleoside analogs plus efavirenz (EFV), nevirapine (NVP), or a...

  • Antiretroviral treatment switch strategies for lowering the costs of antiretroviral therapy in subjects with suppressed HIV-1 viremia in Spain. Llibre, Josep M; Cardona, Gloria; Santos, José R; Andreu, Angels; Estrada, Josep O; Ara, Jordi; Bonafont, Xavier; Clotet, Bonaventura // ClinicoEconomics & Outcomes Research;May2013, Vol. 5, p215 

    Background: The current economic recession in European countries has forced governments to design emergency measures to reduce spending on drugs, including antiretroviral therapy (ART). Switching antiretroviral drugs for others that have the same efficacy and safety profile at a lower cost...

  • Peripheral neuropathy: zalcitabine reassessed. Carey, Peter; Carey, P // International Journal of STD & AIDS;Jul2000, Vol. 11 Issue 7, p417 

    Given that the long-term medical management of HIV infection necessitates making best use of all available antiretrovirals, it is somewhat surprising that the nucleoside analogue reverse transcriptase inhibitor (NRTI) zalcitabine is less commonly used. This may be due to the potential for...

  • Impact of Protease Inhibitors and Other Antiretroviral Treatments on Acquired Immunodeficiency Syndrome Survival in San Francisco, California, 1987–1996. Schwarcz, Sandra K.; Ling Chin Hsu; Vittinghoff, Eric; Katz, Mitchell H. // American Journal of Epidemiology;Jul2000, Vol. 152 Issue 2, p178 

    The authors assessed temporal trends in acquired immunodeficiency syndrome (AIDS) survival for 15,271 persons in San Francisco, California, diagnosed between 1987 and 1996 with an opportunistic illness included in the 1987 AIDS case definition. Predictors of survival were evaluated for 5,686...

  • Synergy of the antiretroviral protease inhibitor indinavir and chloroquine against malaria parasites in vitro and in vivo. Li, Xiaofen; He, Zhengxiang; Chen, Lili; Li, Yayong; Li, Qinyan; Zhao, Siting; Tao, Zhu; Hu, Wen; Qin, Li; Chen, Xiaoping // Parasitology Research;Dec2011, Vol. 109 Issue 6, p1519 

    Many malaria-endemic areas are also associated with high rates of human immunodeficiency virus (HIV) infection. An understanding of the chemotherapeutic interactions that occur during malaria and HIV co-infections is important. Our previous studies have demonstrated that some antiretroviral...

  • HIV combination products. Oversteegen, Lisette; Shah, Mansi; Rovini, Holger // Nature Reviews Drug Discovery;Dec2007, Vol. 6 Issue 12, p951 

    The article reports on the combination of drugs for the treatment of HIV in the U.S. With the introduction of HIV protease inhibitors (PIs) in 1995, it was found that major and prolonged reductions in viral burden could be achieved by the combination of a PI with two NRTIs, known as highly...

  • Ultrafast and high-throughput mass spectrometric assay for therapeutic drug monitoring of antiretroviral drugs in pediatric HIV-1 infection applying dried blood spots. Meesters, Roland J. W.; van Kampen, Jeroen J. A.; Reedijk, Mariska L.; Scheuer, Rachel D.; Dekker, Lennard J. M.; Burger, David M.; Hartwig, Nico G.; Osterhaus, Albert D. M. E.; Luider, Theo M.; Gruters, Rob A. // Analytical & Bioanalytical Chemistry;Sep2010, Vol. 398 Issue 1, p319 

    Kaletra® (Abott Laboratories) is a co-formulated medication used in the treatment of HIV-1-infected children, and it contains the two antiretroviral protease inhibitor drugs lopinavir and ritonavir. We validated two new ultrafast and high-throughput mass spectrometric assays to be used for...

  • Susceptibility of HIV-1 to Tipranavir and Other Antiretroviral Agents in Treatment-Experienced Patients: The UTILIZE Study. Baxter, John D.; Bhatti, Laveeza; Coakley, Eoin; Bartczak, Jennifer; McDonough, Marita; Vinisko, Richard; Piliero, Peter J. // Current HIV Research;Jun2010, Vol. 8 Issue 4, p347 

    Objectives: The primary objective was to assess HIV-1 susceptibility to the protease inhibitor (PI) tipranavir and other antiretroviral (ARV) agents among treatment-experienced patients (TEP). Secondarily, clinicians' use of resistance testing was examined. Methods: UTILIZE was an observational...

  • Pharmacokinetic enhancement of protease inhibitor therapy. King, Jennifer R.; Wynn, Heather; Brundage, Richard; Acosta, Edward P. // Clinical Pharmacokinetics;2004, Vol. 43 Issue 5, p291 

    Combination antiretroviral therapy with two or more protease inhibitors has become the standard of care in the treatment of HIV infection. Dual protein inhibitor (PI) regimens, such as lopinavir/ritonavir, are commonly used as initial PI therapy. As viral resistance increases and the development...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics